{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T21:31:01Z","timestamp":1779399061158,"version":"3.53.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijtb.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T02:26:09Z","timestamp":1703211969000},"page":"194-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Isoniazid-induced hepatotoxicity in patients with latent tuberculosis \u2013 experience from a tuberculosis center"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-8455","authenticated-orcid":false,"given":"Bruno S.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ijtb.2023.12.010_bib1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ijtb.2023.12.010_bib2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bcp.12885","article-title":"Mechanism of isoniazid-induced hepatotoxicity: then and now","volume":"81","author":"Metushi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ijtb.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of Antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijtb.2023.12.010_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/tpj.2016.26","article-title":"Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients","volume":"17","author":"Ben Fredj","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ijtb.2023.12.010_bib6","series-title":"Manual de Tuberculose e Micobact\u00e9rias N\u00e3o Tuberculosas - Recomenda\u00e7\u00f5es\u201c","year":"2020"},{"key":"10.1016\/j.ijtb.2023.12.010_bib7","series-title":"\u201cRelat\u00f3rio de vigil\u00e2ncia e monitoriza\u00e7\u00e3o da tuberculose em Portugal \u2013 Dados definitivos 2020\u201d","year":"2022"},{"key":"10.1016\/j.ijtb.2023.12.010_bib8","article-title":"Immunocompromised travelers - CDC yellow book 2024","author":"Kotton","year":"2023","journal-title":"CDC Yellow Book 2023: Health Inf Int Trav [Internet]"},{"issue":"2","key":"10.1016\/j.ijtb.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ijtb.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gastrohep.2013.03.005","article-title":"Impact of obesity and insulin-resistance on cirrhosis and portal hypertension","volume":"36","author":"Berzigotti","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ijtb.2023.12.010_bib11","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"On behalf of an international consensus panel, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ijtb.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijtb.2023.12.010_bib13","first-page":"1","article-title":"Acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature","volume":"2016","author":"Kabbara","year":"2016","journal-title":"Case Rep Infect Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2023.12.010_bib14","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid rifampin treatment of tuberculosis","volume":"118","author":"Gr\u00f6nhagen Riska","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijtb.2023.12.010_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997270","article-title":"Nonalcoholic fatty liver disease in inflammatory arthritis: relationship with cardiovascular risk","volume":"13","author":"Barbarroja","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijtb.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.1016\/j.jaad.2021.07.069","article-title":"Methotrexate use and liver outcomes in psoriasis and rheumatoid arthritis patients: a commentary on \"Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: a population based study\"","volume":"85","author":"Gau","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijtb.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaad.2021.02.019","article-title":"Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijtb.2023.12.010_bib18","series-title":"Tuberculosis (ERS Monograph)","first-page":"205","article-title":"Adverse anti-tuberculosis drug events and their management","author":"Caminero","year":"2018"},{"key":"10.1016\/j.ijtb.2023.12.010_bib19","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","author":"Niki","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ijtb.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.ijtb.2023.12.010_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01967-2019","article-title":"The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis","volume":"55","author":"Hamada","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2023.12.010_bib22","article-title":"Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia","author":"Juan Cata\u00f1o","year":"2016","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.ijtb.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10067-021-05969-0","article-title":"Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases","volume":"41","author":"Chung","year":"2022","journal-title":"Clin Rheumatol"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723002275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723002275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:11:05Z","timestamp":1749820265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570723002275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0019570723002275"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.12.010","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoniazid-induced hepatotoxicity in patients with latent tuberculosis \u2013 experience from a tuberculosis center","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}